Yuki Takeuchi

Yuki Takeuchi

Auto-generated profile, based on publicly available information

Yuki Takeuchi

Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
KIKanae Imai
Kanae Imai
YTYuki Takeuchi
Yuki Takeuchi
STSeitaro Terakura
Seitaro Terakura
SOShingo Okuno
Shingo Okuno
YAYoshitaka Adachi
Yoshitaka Adachi
HKHitoshi Kiyoi
Hitoshi Kiyoi
Chimeric antigen receptor T (CAR-T) cells targeting multiple antigens (Ag), may reduce the risk of immune escape following the loss of the target Ag and further increase the efficacy of treatment. We developed dual-targeting CAR-T cells that target CD19 and CD37 Ags and evaluated their antitumor effects. CD19/CD37 dual CAR-T cells were generated using cotransduction and simultaneous gene transfer of two types of lentiviral vectors transferring CD19CAR or CD37CAR genes, including the intracellular domains of CD28 and CD3ζ signaling domains. These dual CAR-T cells contained three fractions: CD19/CD37 bispecific CAR-T cells, single CD19CAR-T cells, and single CD37CAR-T cells. In the functional evaluation of CAR-T cells in vitro, CD19/CD37 dual CAR-T cells showed adequate proliferation and cytokine production in response to CD19 and CD37 antigen stimulation alone or in combination. Evaluation of intracellular signaling revealed that dual CAR-T cell–mediated signals were comparable with single CAR-T cells in response to CD19- and CD37-positive B-cell tumors. Although the cytotoxicity of CD19/CD37 dual CAR-T cells in both CD19- and CD37-positive B-cell tumors was similar to that of single CD19 and CD37CAR-T cells, against CD19 and CD37 Ag-heterogeneous tumor, dual CAR-T cells demonstrated significantly superior tumor lysis compared with single CAR-T cells. Furthermore, CD19/CD37 dual CAR-T cells effectively suppressed Ag-heterogeneous Raji cells in a xenograft mouse model. Collectively, these results suggest that CD19/CD37 dual CAR-T cells may be effective target-Ag-loss B-cell tumor models in vitro and in vivo, which represents a promising treatment for patients with relapsed/refractory B-cell malignancies.

4 March 2024
Verified
Other
Open access
KIKanae Imai
Kanae Imai
YTYuki Takeuchi
Yuki Takeuchi
STSeitaro Terakura
Seitaro Terakura
SOShingo Okuno
Shingo Okuno
YAYoshitaka Adachi
Yoshitaka Adachi
HKHitoshi Kiyoi
Hitoshi Kiyoi
Supplemental Figure S2. Evaluation of cytokine production against tumor cells isolated from patients who relapsed after CAR-T cell therapy. A, Expression of CD19, CD20, and CD37 in diffuse large B-cell lymphoma cells from a relapsed patient after a treatment with tisagenlecleucel. B, Intracellular IL-2 or IFN-γ positive cells after stimulation with the patient tumor cells at an E:T ratio 1:1 for 4 h.

4 March 2024
Verified
Other
Open access
KIKanae Imai
Kanae Imai
YTYuki Takeuchi
Yuki Takeuchi
STSeitaro Terakura
Seitaro Terakura
SOShingo Okuno
Shingo Okuno
YAYoshitaka Adachi
Yoshitaka Adachi
HKHitoshi Kiyoi
Hitoshi Kiyoi
Supplemental Figure S1. CD19 and CD37 expression of EBV-LCL. EBV-LCL was stained with CD19-PE and CD37-FITC mAb, respectively. Grey tinted area indicated isotype control staining.

4 March 2024
Verified
Other
Open access
KIKanae Imai
Kanae Imai
YTYuki Takeuchi
Yuki Takeuchi
STSeitaro Terakura
Seitaro Terakura
SOShingo Okuno
Shingo Okuno
YAYoshitaka Adachi
Yoshitaka Adachi
HKHitoshi Kiyoi
Hitoshi Kiyoi
Supplemental Figure S2. Evaluation of cytokine production against tumor cells isolated from patients who relapsed after CAR-T cell therapy. A, Expression of CD19, CD20, and CD37 in diffuse large B-cell lymphoma cells from a relapsed patient after a treatment with tisagenlecleucel. B, Intracellular IL-2 or IFN-γ positive cells after stimulation with the patient tumor cells at an E:T ratio 1:1 for 4 h.

4 March 2024
Verified
Other
Open access
KIKanae Imai
Kanae Imai
YTYuki Takeuchi
Yuki Takeuchi
STSeitaro Terakura
Seitaro Terakura
SOShingo Okuno
Shingo Okuno
YAYoshitaka Adachi
Yoshitaka Adachi
HKHitoshi Kiyoi
Hitoshi Kiyoi
Supplemental Figure S3. Analysis of differentiation markers of CAR-T cells. Each CAR-T cells and tEGFR-T cells were stimulated with CD19/CD37 positive Raji cells at a 1:5 ratio every 7 days and stained for CD62L, CD45RA, CCR7, CD27 and CD28. A, B, Summary data of the percentage of CD45RA-/CD62L+ central memory T (TCM) cell fraction (A) and CD45RA-/CD62L- effecter memory T (TEM) cell fraction (B). C–E, Summary data of the percentage of CCR7-/CD27+/CD28+ early TEM cell fraction (C), CCR7-/CD27+/CD28- late TEM cell fraction (D) and CCR7-/CD27-/CD28- effecter T cell fraction (E). Data represent mean ± SEM from five different donors (two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001).

4 March 2024
Verified
Other
Open access
KIKanae Imai
Kanae Imai
YTYuki Takeuchi
Yuki Takeuchi
STSeitaro Terakura
Seitaro Terakura
SOShingo Okuno
Shingo Okuno
YAYoshitaka Adachi
Yoshitaka Adachi
HKHitoshi Kiyoi
Hitoshi Kiyoi
Supplemental Figure S1. CD19 and CD37 expression of EBV-LCL. EBV-LCL was stained with CD19-PE and CD37-FITC mAb, respectively. Grey tinted area indicated isotype control staining.